UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is actively enrolling patients in the BACKBEAT pivotal study of AVIM therapy in hypertensive pacemaker patients NEW HOPE, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patie ...

Bloomberg/Bloomberg via Getty Images Thesis In my previous article about Medtronic plc (NYSE:MDT), released in I assigned a fair price of $137.6 which at the time indicated a 71.82% upside. The reason for this targets was because I updated my models following Q2 2024 released in November 30, 2023, and I explained how weight loss drugs will not affect Medtronic. This last one drove me to upgrade Medtronic from "buy" to "strong buy". So far, my thesis has materialized, since Medtronic reported Q3 2024 and it ...

(Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesDeal Overview On February 20, 2024, Medtronic MDT Corporation (NYSE: MDT, $85.90, Market Capitalization: $114.2 billion) in its 3Q24 earnings call announced that it no longer plans to spin-off its Patient Monitoring and Respiratory Intervention (PMRI) Business mainly on improved performance in Patient Monitoring business. Currently Medtronic business consist Cardiovascular Portfolio, Medic ...

Medtronic (MDT 0.06%) is a leading medical device company that aims to simplify patients' everyday lives. And with a broad presence that spans 150 countries, treating more than 70 health conditions, Medtronic has the potential to be a great healthcare investment to buy and hold.Unfortunately, the company has battled multiple headwinds in recent times, which has led to uninspiring financials and a disappointing stock performance. In the past three years, shares of Medtronic have fallen by 24%. Can the next t ...

Shares of Medtronic (MDT 1.69%) climbed as much as 3.3% early Tuesday, and then settled to close up around 1.7%, after the medical-device company announced strong fiscal third-quarter results and impressive forward guidance.On Medtronic's "solid execution," durable growthFor its fiscal third-quarter 2024, ended Jan. 26, Medtronic's revenue grew 4.7% year over year (4.6% organically) to $8.089 billion, translating to roughly flat adjusted (non-GAAP) earnings of $1.728 billion, or $1.30 per share -- though th ...

Medtronic plc (MDT) reported adjusted earnings per share (EPS) of $1.30 in third-quarter fiscal 2024, in line with the year-ago quarter’s EPS. The figure beat the Zacks Consensus Estimate by 3.2%.Without certain one-time adjustments — including restructuring and associated costs, amortization and acquisition-related costs, among others — GAAP EPS were 99 cents, up 7.6% from the year-ago quarter’s reported figure.Total RevenuesWorldwide revenues in the reported quarter grossed $8.09 billion, up 4.7% year ove ...

Key TakeawaysBetter-than-expected sales of heart and diabetes devices helped Medtronic beat fiscal third-quarter profit and sales estimates.The medical devices firm also raised its full-year outlook for the current fiscal year that will end in late April.Medtronic said it was exiting its money-losing ventilator business and combining the remaining parts of its Patient Monitoring and Respiratory Interventions division into one unit.Shares of Medtronic PLC (MDT) gained Tuesday after the medical technology fir ...

Medtronic plc (NYSE:MDT) Q3 2024 Earnings Conference Call February 20, 2024 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Brad Welnick - Vice President, Investor Relations Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Que Dallara - Executive Vice President and President, Diabetes Mike Marinaro - Executive Vice President and President, ...

For the quarter ended January 2024, Medtronic (MDT) reported revenue of $8.09 billion, up 4.7% over the same period last year. EPS came in at $1.30, compared to $1.30 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $7.95 billion, representing a surprise of +1.73%. The company delivered an EPS surprise of +3.17%, with the consensus EPS estimate being $1.26.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...